Secondary Header Menu
HIV, RSV, Coronavirus and other viruses
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group's Infectious Disease Virtual Conference
April 28, 2020 at 8:00 AM EDT
SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group.
Presentation Information:
Panel: "Antifungals"
Date: Tuesday, May 5, 2020
Time: 12:15 – 1:45 PM ET
Panel: "COVID-19 (Therapeutics)"
Time: 3:45 – 5:00 PM ET
Registration for Live Event: http://go.pardot.com/l/652223/2020-04-02/j1mqg
About Cidara Therapeutics
Cidara is developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections. The Company's portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to therapies targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Karen O'Shea, Ph.D.
LifeSci Communications
koshea@lifescicomms.com
Source: Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
e: info@cidara.com
© 2021 Cidara Therapeutics, Inc. | Terms of Use | Privacy and Cookies Policy